Prokanazol

General characteristics. Structure:

Active agents: 100 mg of an itrakonazol.

Pharmacological properties:

Itrakonazol, derivative triazole of the 1st generation — antifungal fungistatic broad-spectrum agent. Suppression of enzyme 14alfademetilazy breaks ergosterol synthesis in cells of micromycetes. Ergosterol represents the vital component of membrane cells of mushrooms. Disturbance of its synthesis is a basis of antifungal effect. Itrakonazol is effective against the infections caused by dermatophytes (Epidermophyton floccosum, Trichophyton spp., Microsporum spp.), yeast (Cryptococcus neoformans, Pityrosporum spp., Candida spp. vKetn ě C. albicans, C. glabrata, C. krusei) and other opportunistic micromycetes (Aspergillus spp., Histoplasma spp., etc.).

Indications to use:

Mycoses. Gynecologic indications (vulvovaginal candidiasis), dermatological indications (chromophytosis; a dermatomycosis, candidiasis of a mucous membrane of an oral cavity, an onychomycosis), ophthalmologic indications (a fungal keratitis) and system mycoses (a system aspergillosis and candidiasis, a cryptococcosis — including cryptococcal meningitis, histoplasmosis, a sporotrichosis, a paracoccidioidomycosis, a zymonematosis, chromomycosis and others). Prokanazol is shown for therapy of adults and children weighing over 40 kg.

Route of administration and doses:

• Vulvovaginal candidiasis: on 200 mg of 1 times a day 3 days or on 200 mg 2 times a day 1 day;
• Chromophytosis: on 200 mg of 1 times a day 7 days;
• Dermatomycoses: on 200 mg of 1 times a day 7 days or on 100 mg of 1 times a day 15 days;
• Candidiasis of a mucous membrane of an oral cavity: 100 mg of 1 times a day 15 days;
• Mycotic keratitis: 200 mg of 1 times a day within 21 days;
• Onychomycosis: pulse therapy on 200 mg 2 times a day within 1 week, then a three-week break; pulse is repeated 2 times (nails on hands), by 3 times (nails standing).
Prokanazol accept right after meal.

Features of use:

The patient with congestive heart failure (also in the anamnesis) to accept итраконазол only if the advantage of therapy certainly exceeds risk (negative inotropic effect of an itrakonazol), patients with damage of a liver or kidneys have only limited data therefore the increased care is recommended. The drugs reducing acidity of a stomach worsen absorption of an itrakonazol therefore antacids accept not earlier than in 2 hours after reception of an itrakonazol; the patient with an achlorhydria or the accepting H2 blockers or IPP recommend to wash down drug with drink of acid character (e.g. Coca-Cola). Prokanazol nestles close in a small amount in maternal milk therefore breastfeeding is not recommended.

Side effects:

Disorders of a GIT (abdominal pains, nausea, vomiting, diarrhea, lock), disturbances of skin and hypodermic fabric (rash, urticaria, alopecia, itch), disturbances of a liver.

Interaction with other medicines:

Strong inductors of CYP3A4 cytochrome (rifampicin, рифабутин, фенытоин, carbamazepine, phenobarbital, an isoniazid) reduce efficiency of an itrakonazol; CYP3A4 inhibitors (ритонавир, индинавир, кларитромицин, erythromycin) on the contrary increase its biological availability. Monitoring of levels of a blood plasma and also possible decrease in doses it is necessary at peroral anticoagulants, inhibitors of HIV proteases, blockers of calcium channels (dihydropyridines, verapamil), some immunosuppressive means, some glucocorticoids, digoxin, midazolam, an alprazolam, fentanyl, a reboksetin, a repaglinid.

Contraindications:

Hypersensitivity to an itrakonazol. Simultaneous therapy by CYP3A4 substrates, e.g. terfenadiny, astemizoly, bepridily, mizolastiny, tsizapridy, dofetilidy, and sertindoly can extend with quinidine, Pimozidum QT interval. Further симвастатин, ловастатин, аторвастатин, to triazoles, midazolam, ergot alkaloids, элетриптан, нисолдипин. Pregnancy except for life of the menacing cases. Contraception during all therapy by Prokanazol and after its termination prior to the beginning of the following periods is necessary for women of reproductive age.

Overdose:

There are no data on overdose.

Storage conditions:

List B.: In the dry place, at a temperature not above 25 °C.

Issue conditions:

According to the recipe

Packaging:

4, 6, 14, 18, 28 or 30 capsules.